# A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

> **NCT03713957** · PHASE2 · COMPLETED · sponsor: **Alkahest, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** GRF6021
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03713957
- **Lead sponsor:** Alkahest, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-12
- **Primary completion:** 2020-07-20
- **Final completion:** 2020-07-20
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2022-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03713957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03713957, "A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03713957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*